Full Text | PDF

J Cancer 2020; 11(17):5150-5161. doi:10.7150/jca.39467 This issue Cite

Research Paper

Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia

Rui Lai^1*, Weilong Zhang^2*, Xue He^3*, Xinhui Liao⁴, Xiaoni Liu⁴, Wei Fu⁵, Ping Yang², Jing Wang², Kai Hu², Xiaoliang Yuan⁴, Xiuru Zhang^3✉, Hongmei Jing^2✉, Weiyou Liu^4✉

1. Department of the Respiratory medicine, The People's Hospital of Ruijin City, Ruijin, 342500, China.
2. Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
3. Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, Beijing, 100050, China.
4. Department of Respiratory medicine, First Affiliated Hospital Gannan Medical University, Ganzhou, 341000, China.
5. Peking University Third Hospital, Beijing, 100191, China.
*These authors contributed equally to this work.

✉ Corresponding author: Dr Weiyou Liu, Department of Respiratory Medicine, First Affiliated Hospital Gannan Medical University, No. 23 Qingnian Road, Zhanggong District, Ganzhou, 341000, China. E-mail: gzweiyoucom, Tel.: +86-13707079543; Dr Hongmei Jing, Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, P.R. China. E-mail: drjinghmcom, Tel.: +86-10-8226-6785; Dr Xiuru Zhang, Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, Beijing, 100050, China. E-mail: zhangxiuru999com. More

Abstract

ACTL10 is a member of the actin family; however, despite previous studies suggesting that certain proteins in this family may be related to the pathogenesis of leukemia, to the best of our knowledge, no studies to date have demonstrated any association between ACTAL10 and leukemia. Thus, the present study aimed to determine the association between ACTL10 expression levels, DNA methylation levels and the clinical prognosis in cytogenic normal acute myeloid leukemia (CN-AML). Data from seventy-five patients with CN-AML and patients with AML treated with chemotherapy or allogeneic hematopoietic stem cell transplantation were obtained from The Cancer Genome Atlas (TCGA) dataset and were used to analyze the clinical prognosis of ACTL10 RNA expression levels and DNA methylation levels. In addition, the study also investigated the combined clinical prognosis of ACTL10 RNA expression levels and ACTL10 DNA methylation levels in 74 patients with CN-AML from the TCGA dataset. ACTL10 RNA expression levels were observed to be highly expressed in patients with CD34⁺/CD38⁺ AML (P<0.01). Both ACTL10 RNA expression levels and DNA methylation were found to be independent prognostic factors for patients with CN-AML; patients with CN-AML in the ACTL10 RNA-high expression group had an increased EFS (P=0.0016) and OS (P=0.014) and patients in ACTL10 DNA methylation-low group also demonstrated a long EFS (P<0.0001) and OS (P=0.004). Notably, integrating ACTL10 RNA expression levels and ACTL10 DNA methylation levels could more accurately predict the prognosis of patients with CN-AML (EFS and OS, P<0.0001). In conclusion, the findings of the present study suggested that the high RNA expression levels and low DNA methylation levels of ACTL10 may predict a good prognosis in patients with CN-AML.

Keywords: ACTL10, CN-AML, RNA expression, DNA methylation

Citation styles

©2024 Ivyspring International Publisher. Terms of use